glp 1 injections before and after GLP-1 GIP Agonist Weight Management Body Image Distortion After Weight

zellikle Alzheimer ve Parkinson hastalklarnda yaplan almalar, GLP-1 ilalarnn beyin hcrelerini koruyucu etkiler gsterebileceini ne srmektedir

After a median follow-up of two years, new or worsening nephropathy occurred less often in patients treated with semaglutide (HR = 0.64 (0.460.88), p = 0.005)

These medications, except exenatide, are safe for patients with mild to severe renal impairment without dose adjustments (73, 74)

GLP-1 microdosing schedule Microdosing schedules usually follow the same weekly cadence as standard GLP-1 medications, just at lower doses

30 , 31 The FLOW trial demonstrated that, compared to placebo, randomization to semaglutide reduced the risk of kidney-related complications by 24% (HR: 0.76, 95% CI 0.66, 0.88) in patients with diabetes and chronic kidney disease